Intelligence Feed event · Equity · 2026-10-13

    Abbott Gains 2.23% to $101.82 on Projected 9.2% Q3 EPS Growth to $1.42

    Question

    Abbott Gains 2.23% to $101.82 on Projected 9.2% Q3 EPS Growth to $1.42

    Direct answer

    Abbott Laboratories advanced 2.23% to $101.82 on October 12, 2026, defying broader market consolidation. The healthcare company is set to report its Q3 earnings results on October 21, 2026. Analysts project quarterly earnings of $1.42 per share, representing a 9.23% rise year-over-year, supported by $12.91 billion in revenue (up 13.52% YoY). The projected acceleration reflects steady demand across cardiovascular devices and core laboratory diagnostics.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-13
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Abbott Gains 2.23% to $101.82 on Projected 9.2% Q3 EPS Growth to $1.42”, revision 1, evidence through 2026-10-13. https://marketontology.com/market-events/2026-10-13/abbott-gains-2-23-to-101-82-on-projected-9-2-q3-eps-growth-to-1-42-334349

    EQUITY
    Abbott Gains 2.23% to $101.82 on Projected 9.2% Q3 EPS Growth to $1.42
    Abbott Laboratories advanced 2.23% to $101.82 on October 12, 2026, defying broader market consolidation. The healthcare company is set to report its Q3 earnings results on October 21, 2026. Analysts project quarterly earnings of $1.42 per share, representing a 9.23% rise year-over-year, supported by $12.91 billion in revenue (up 13.52% YoY). The projected acceleration reflects steady demand across cardiovascular devices and core laboratory diagnostics.
    ABT
    Impact
    65
    OCT 13
    SIG
    85%
    ABT
    Abbott Gains 2.23% to $101.82 on Projected 9.2% Q3 EPS Growth to $1.42
    Abbott Laboratories advanced 2.23% to $101.82 on October 12, 2026, defying broader market consolidation. The healthcare company is set to report its Q3 earnings results on October 21, 2026. Analysts project quarterly earnings of $1.42 per share, representing a 9.23% rise year-over-year, supported by $12.91 billion in revenue (up 13.52% YoY). The projected acceleration reflects steady demand across cardiovascular devices and core laboratory diagnostics.
    → Medical device procedure volume expansion and diagnostic equipment sales support double-digit top-line growth, expanding operating margins ahead of quarterly reporting.
    Impact
    Abbott Laboratories advanced 2.23% to $101.82 on October 12, 2026, defying broader market consolidation. The healthcare company is set to report its Q3 earnings results on October 21, 2026. Analysts project quarterly earnings of $1.42 per share, representing a 9.23% rise year-over-year, supported by $12.91 billion in revenue (up 13.52% YoY). The projected acceleration reflects steady demand across cardiovascular devices and core laboratory diagnostics.
    Affected
    ABT
    Transmission
    Medical device procedure volume expansion and diagnostic equipment sales support double-digit top-line growth, expanding operating margins ahead of quarterly reporting.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ABTdevice volume and diagnostic sales revenue accelerationUp1-4wStock gained 2.23% to $101.82 with consensus projecting 13.52% revenue growth on Oct 21.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month